Home › Trial NCT06592625
Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients
- Trial IDNCT06592625
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrollment60
- Start date2024-09-20
- ConditionsUntreated Early-stage or Locally Advanced Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.